Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hillard Lazarus

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Research Square|October 4, 2023
Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) TrialEhsan Malek, Jeries Kort, Leland Metheny, et al.
Blood|March 27, 2004
Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemiasElisabeth Paietta, Adolfo A Ferrando, Donna Neuberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2009
Defining the intensity of conditioning regimens: working definitionsAndrea Bacigalupo, Karen Ballen, Doug Rizzo, et al.
Transplantation and Cellular Therapy|February 16, 2022
A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult DonorsFolashade Otegbeye, Brenda Cooper, Paolo Caimi, et al.
Blood|November 27, 2013
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemiaAdele K Fielding, Jacob M Rowe, Georgina Buck, et al.
Haematologica|May 19, 2019
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?Miguel-Angel Perales, Benjamin Tomlinson, Mei-Jie Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2012
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomasDavid S Hong, Razelle Kurzrock, Jeffrey G Supko, et al.
Journal of Cancer|May 23, 2017
Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell TransplantationYee Chung Cheng, Yushu Shi, Mei-Jie Zhang, et al.
Transplantation and Cellular Therapy|April 18, 2021
The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 PandemicJack W Hsu, Nosha Farhadfar, Hemant Murthy, et al.
Leukemia Research|November 13, 2021
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trialSelina M Luger, Victoria X Wang, Jacob M Rowe, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Research Square|October 4, 2023
Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) TrialEhsan Malek, Jeries Kort, Leland Metheny, et al.
Blood|March 27, 2004
Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemiasElisabeth Paietta, Adolfo A Ferrando, Donna Neuberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2009
Defining the intensity of conditioning regimens: working definitionsAndrea Bacigalupo, Karen Ballen, Doug Rizzo, et al.
Transplantation and Cellular Therapy|February 16, 2022
A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult DonorsFolashade Otegbeye, Brenda Cooper, Paolo Caimi, et al.
Blood|November 27, 2013
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemiaAdele K Fielding, Jacob M Rowe, Georgina Buck, et al.
Haematologica|May 19, 2019
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?Miguel-Angel Perales, Benjamin Tomlinson, Mei-Jie Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2012
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomasDavid S Hong, Razelle Kurzrock, Jeffrey G Supko, et al.
Journal of Cancer|May 23, 2017
Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell TransplantationYee Chung Cheng, Yushu Shi, Mei-Jie Zhang, et al.
Transplantation and Cellular Therapy|April 18, 2021
The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 PandemicJack W Hsu, Nosha Farhadfar, Hemant Murthy, et al.
Leukemia Research|November 13, 2021
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trialSelina M Luger, Victoria X Wang, Jacob M Rowe, et al.
Pageof 5